Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: Treatment intervals and clinical outcomes
    Journal Article

    Wright, J. L.; Cordeiro, P. G.; Ben-Porat, L.; Van Zee, K. J.; Hudis, C.; Beal, K.; McCormick, B.
    International Journal of Radiation Oncology, Biology, Physics (2008)

    Fulltext@MSK | Save
  • Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    Journal Article

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Tan, L. K.; Edwards, C.; Dugan, U.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer
    Journal Article

    Traina, T. A.; Poggesi, I.; Robson, M.; Asnis, A.; Duncan, B. A.; Heerdt, A.; Dang, C.; Lake, D.; Moasser, M.; Panageas, K.; more...
    Breast Cancer Research and Treatment (2008)

    Fulltext@MSK | Save
  • Occult axillary node metastases in breast cancer are prognostically significant: Results in 368 node-negative patients with 20-year follow-up
    Journal Article

    Tan, L. K.; Giri, D.; Hummer, A. J.; Panageas, K. S.; Brogi, E.; Norton, L.; Hudis, C.; Borgen, P. I.; Cody, H. S. 3rd
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • EP(2) and EP(4) receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange
    Journal Article

    Subbaramaiah, K.; Hudis, C.; Chang, S. H.; Hla, T.; Dannenberg, A. J.
    Journal of Biological Chemistry (2008)

    Fulltext@MSK | Save
  • Cyclooxygenase-2-derived prostaglandin E(2) stimulates Id-1 transcription
    Journal Article

    Subbaramaiah, K.; Benezra, R.; Hudis, C.; Dannenberg, A. J.
    Journal of Biological Chemistry (2008)

    Fulltext@MSK | Save
  • Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma
    Journal Article

    Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.; Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Joseph Germino, F.; Krown, S. E.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Breast tumor cells with P13K mutation or HER2 amplification are selectively addicted to Akt signaling
    Journal Article

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    PLoS ONE (2008)

    Fulltext@MSK | Save
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840
    Journal Article

    Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Muss, H.; Marcom, P. K.; Gipson, G.; Burstein, H.; Lake, D.; Shapiro, C. L.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Metastatic breast cancer: How far we've come - The Higgins/Wolff article reviewed [Therapeutic options in the management of metastatic breast cancer]
    Journal Article

    Seidman, A. D.
    Oncology (Norwalk) (2008)

    Fulltext@MSK | Save